Linomide administration following bone marrow transplantation in mice

Cancer Immunology, Immunotherapy

Volumn 51, Issue 11-12, 2002, Pages 596-602

  Weiss, Lola ^a   Abdul Hai, Ali ^a   Shufaro, Yoel ^a   Reich, Shoshanna ^a   Slavin, Shimon ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

B cell leukemia; Bone marrow graft versus leukemia effect; Linomide; Murine leukemia; Transplantation

Indexed keywords

ROQUINIMEX; WATER;

ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOIMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; B CELL LEUKEMIA; BONE MARROW TRANSPLANTATION; CANCER CELL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GRAFT SURVIVAL; GRAFT VERSUS LEUKEMIA EFFECT; IMMUNE RESPONSE; IMMUNOMODULATION; ISOGRAFT; LEUKEMIA; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TARGET ORGAN;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BONE MARROW TRANSPLANTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HYDROXYQUINOLINES; KILLER CELLS, NATURAL; LEUKEMIA, B-CELL; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL;

EID: 0036453487     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-002-0311-5     Document Type: Article

References (34)

1. Slavin S (1996) Effector cells of experimental and clinical cellular adoptive immunobiology. Cell Ther 2:18
2. Cohen P, Vourka-Karussis U, Weiss L, Slavin S (1993) Spontaneous and IL-2 induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens. J Immunol 151:4803
3. Vourka-Karussis U, Karussis D, Ackerstein A, Slavin S (1995) Enhancement of graft versus leukemia effect (GVL) with recombinant human interleukin 2 (rIL-2) following bone marrow transplantation in a murine model for acute myeloid leukemia in SJL/J mice. Exp Hematol 23:196
4. Weiss L, Reich S, Slavin S (1992) Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders. I. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL2-activated cell-mediated immunotherapy. Cancer Invest 10:19
5. Weiden P, Fluornoy N, Sanders JE, Sullivan KM, Thomas ED (1981) Antileukemic effect of graft versus host disease contributes to improved survival after allogeneic marrow transplantation. Transplantation 13:248
6. Horowitz M, Gale RP, Sondel PM (1990) Graft versus leukemia reactions after bone marrow transplantation. Blood 75:555
7. Slavin S, Naparstek E, Nagler A, Ackerstein A, Kapelushnik J, Or R (1995) Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol 23:1553
8. Slavin S, Naparstek E, Nagler A, Ackerstein A, Samuel S, Kapelushnik J, Brautbar C, Or R (1996) Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse post allogeneic bone marrow transplantation. Blood 87:2195
9. Slavin S, Ackerstein A, Naparstek E, Or R, Weiss L (1990) Phenomenon: The graft-versus-leukemia (GVL) phenomenon: Is GVL separable from GVHD? Bone Marrow Transplant 6:155
10. Kalland T, Alm G, Standhalske T (1985) Augmentation of mouse natural killer cell activity by LS 2616, a new immunomodulator. J Immunol 134:3956
11. Larson EL, Joki A, Standhalski T (1987) Mechanism of action of the new immunomodulator LS 2616 on T cell responses. J Immunopharmacol 9:425
12. Wanders A, Vogt P, Karlsson-Parra A, Wonigkeit K, Gerdin B, Tufveson G (1991) Evidence that LS -2616 (linomide) causes acute rejection of rat allografts protected by cyclosporine but not of long-term surviving allografts. Transplantation 52:234
13. Rapoport MJ, Weiss L, Mor A, Bistritzer T, Slavin S (1996) Prevention of autoimmune diabetes by linomide in nonobese diabetic (NOD) mice is associated with up-regulation of the TCR-mediated activation of p21(ras). J Immunol 157(10):4721
14. Karussis DM, Slavin S, Vourka-Karussis U, Lehmann D, Mizrachi-Koll R, Ovadia H, Kalland T, Abramsky O (1993) Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide). Proc Natl Acad Sci USA 90:6400
15. 1 hybrid mice. Immunology 59:589
16. Tarkowski A, Gunnarsson K, Nilsson LA, Lindholm L, Stal-handske T (1986) Successful treatment of autoimmunity in MRL/I mice with LS-2616, a new immunomodulator. Arthritis Rheum 29:1405
17. Slavin S, Sidi H, Weiss L, Rosenmann E, Kalland T, Gross D (1993) Prevention of insulin-dependent diabetes mellitus (IDDM) and autoimmune insulitis in NOD mice by inomide, a new immunoregulator of autoimmune diseases. EOS J Immunol Immunopharmacol 13:129
18. Slavin S, Sidi H, Weiss L, Rosenmann E, Kalland T, Gross D (1993) Linomide - A new treatment for autoimmune diseases - The potential for treatment of type I diabetes. Diabetes Metab Rev 9(4):311
19. Gross DJ, Sidi H, Kalland T, Rosenmann E, Weiss L, Slavin S (1994) Prevention of diabetes in non-obese diabetic mice by linomide, a novel immunomodulating drug. Diabetologia 37:1195
20. Kalland T (1986) Effects of the immunomodulator LS 2616 on growth and metastasis of the murine B16-F10 melanoma. Cancer Res 46:3018
21. Rowe JM, Ryan DH, Nilsson BI, Liesveld JL, DiPersio JF, Larsson L, Simonsson B (1996) Chronic myelogenous leukemia treated with autologous bone marrow transplantation followed by the immunomodulator roquinimex (linomide). In: 7th International Symposium on Autologous Bone Marrow Transplantation. Arlington, USA
22. Weiss L, Reich S, Slavin S (1990) Effect of cyclosporine A and methylprednisolone on the graft-versus-leukemia effects across major histocompatibility barriers in mice following allogeneic bone marrow transplantation. Bone Marrow Transplant 6(4):229
23. Bengtsson M, Simonsson B, Carlsson K, Nilsson B, Smedmyr B, Termander B, Oberg G, Totterman T (1992) Stimulation of NK cell, T cell, and monocyte functions by the novel immu-nomodulator linomide after autologous bone marrow transplantation. Transplantation 53:882
24. Slavin S, Strober S (1978) Spontaneous murine B-cell leukemia. Nature 272:624
25. Hokland M, Jorgensen H, Holm MS, Shimonsson B, Nilsson B, Bengtsson M, Hokland P (1999) Natural effector cells in patients with acute myeloid leukemia treated with the immu-nomodulator linomide after autologous bone marrow transplantation. Eur J Haematol 63:25
26. Rosenberg S, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E. Uetto JT, et al (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. New Engl J Med 313:(23)1485
27. Slavin S, Ackerstein A, Weiss L (1988) Adoptive immunotherapy in conjunction with bone marrow transplantation - Amplification of natural host defense mechanisms against cancer by recombinant IL2. Nat Immun Cell Growth Regul 7:180
28. Ackerstein A, Kedar E, Slavin S (1991) Use of recombinant human interleukin-2 in conjunction with syngeneic bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders. Blood 78:1212
29. Gaspari AA, Cheng SF, DiPersio JF, Rowe JM (1995) Roquinimex-induced graft-versus-host reaction after autologous bone marrow transplantation. J Am Acad Dermatol 33:711
30. Vaz F, Silva MR, Ascensao JL (1995) Enhanced lymphokine-activated killer cell activity by an immunomodulator, roquinimex. Br J Cancer 72(6):1498
31. Rowe JM, Rapoport AP, Ryan DH, Nilsson BI, Duerst RE, Packman CH, Abboud CN, DiPersio JF, Linder T, Wang N, Simonsson B, Lievsveld JL (1999) Treatment of chronic myelogenous leukemia with autologous bone marrow transplantation followed by roquinimex. Bone Marrow Transplant 24(10):1057
32. Ohsuga Y, Rowe JM, Liesveld J, Burns RP, Gaspari AA (2000) Dermatologic changes associated with roquinimex immunotherapy after autologous bone marrow transplant. J Am Acad Dermatol 43:437
33. Simonsson B, Totterman T, Hokland P, Lauria F, Carella AM, Fernandez MN, Rozman C, Ferrant A, de-Witte T, Zander AR, Meier K, Hansson F, Nilsson BI (2000) Roquinimex (linomide) vs placebo in AML after autologous bone marrow transplantation. Bone Marrow Transplant 25(11):1121
34. 2 cytokine production by lymphocytes. Immunol Lett 67(3):203